Slide 1: Second Quarter 2026 Operating & Financial Results
Second Quarter 2026 Operating & Financial Results Conference Call / Webinar August 14th, 2026 9AM Eastern Time NASDAQ :LTRN
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements r
Slide 3: Contents and Speakers
Contents Speakers Panna Sharma David Margrave 01 Introduction CEO and President CFO 02 2026 Q2 Highlights 03 Financial Highlights 04 Q&A 2
Slide 4: 2nd Quarter Highlights 1 of 4
2026 2nd Quarter Highlights ü Open-Medicine AI (OMAI) established as a separate company with board-approved commercial licensing 1of 4 agreements executed, operating the multi-agentic AI co-scientist platform previously launched as withZeta.ai. OMAI is currently wholly owned by Lantern and intends t
Slide 5: 2nd Quarter Highlights 2 of 4
2026 ü LP-300 - HARMONIC™ benefit deepens with treatment 2nd Quarter duration: Median progression-free survival of 8.9 months in EGFR exon 21 L858R patients treated through up to six cycles, a hazard ratio of 0.37 (95% CI 0.15–0.89) favoring the L858R Highlights subgroup, a 77% clinical benefit rate
Slide 6: 2nd Quarter Highlights 3 of 4
2026 2nd Quarter ü EMA clearance in bladder cancer for LP-184 (zirdafulven): an investigator-initiated Phase 1b/2 trial of Highlights zirdafulven at Rigshospitalet in Denmark, among the first studies to prospectively select patients using a dual biomarker strategy — PTGR1 overexpression combined wit
Slide 7: 2nd Quarter Highlights 4 of 4
2026 2nd Quarter ü USPTO Notice of Allowance received for claims covering a Highlights three-gene expression signature used to select patients for treatment with LP-184 across four solid tumor indications. Financial position: Cash, cash equivalents, and marketable 4of 4 ü securities of approximately
Slide 8: Open-Medicine AI: Expanding Lantern's AI Opportunity Beyond Oncology
Open-Medicine AI: Expanding Lantern’s AI Opportunity Beyond Oncology A strategic step to commercialize and expand Lantern’s multi-agent AI co-scientist platform A strategic evolution of withZeta.ai From idea to medicine at the speed of insight $10B+ Separate Commercial Lantern-owned company licenses
Slide 9: Multi-agent Collaboration at the Speed of Insight
Multi-agent Collaboration at the Speed of Insight Instead of a single monolithic model, Open Medicine AI orchestrates a swarm of specialized agents that mirror the roles of a high-performing discovery and development team. Medicinal Chemist Computational Biologist Pharmacologist Design & optimize Ta
Slide 10: Target Lesion Decreased in Over 70% of Evaluable L858R Patients
Target Lesion Decreased in Over 70% of Evaluable L858R Patients Percent change in cancer lesion size over time Percent change in cancer lesion size by patient Protocol Amendments following FDA Type C Interaction 1 Focus enrollment EGFR Exon 21 L858R patients 2 Convert design Migrate to Phase 2 singl
Slide 11: LP-300 Shows Deep Tumor Responses in Patients with EGFR L858R
LP-300 Shows Deep Tumor Responses in Patients with EGFR L858R – Mutated NSCLC As of 11 May, 2026 Disease Control Rate = 87%* PFS > 12 months Observed in 3 Patients *** ** *one patient excluded from the bar graph: brain lesion identified post-randomization, before the scheduled protocol specified tum
Slide 12: Lantern's Diverse & Unique AI Driven Pipeline of Drug Programs
Lantern’s Diverse & Unique AI Driven Pipeline of Drug Programs Lantern has 10 disclosed drug programs including the Phase 2 HarmonicTM trial Lantern Pharma (NASDAQ: LTRN) Program Indication Preclinical Phase 1a Phase 1b Phase II Non-Small Cell Lung Cancer for Never Smokers LP-300 Market Potential: $
Slide 13: Twelve FDA Designations Demonstrate our Data-driven, AI-enabled Approach
Twelve FDA Designations Demonstrate our Data-driven, AI-enabled Approach to Transform Drug Development & Strengthen Commercial Value 12
Slide 14: Phase 1b/2 Biomarker Driven Trial of LP-184 in Advanced Urothelial Carcinoma
A Phase 1b/2 Biomarker Driven Trial of LP-184 in Advanced Urothelial Carcinoma (Bladder) with PTGR1-Positive and TC-NER/HR Deficient Single agent, starting dose = 0.39 mg/kg Dose de-escalation LP-184 D1,8 (21d) Phase 1b Determine the optimal LP-184 dose 3+3 (total n=3~18) Simon first stage (n=13) If
Slide 15: Planned Phase 1b/2 Trial of LP-184 Monotherapy in TNBC
A Planned Phase 1b/2 Trial of LP-184 Monotherapy in Relapsed/ Refractory Advanced/Metastatic TNBC with HR-deficiency Single agent, 2-dose levels LP-184 D1,8 (21d) Phase 1b • Cohort A (n≥15) Determine RP2D • Cohort B (n≥15) Simon first stage (n=15) If >1 Phase 2 Objective Simon second stage (n=10) Ph
Slide 16: LP-184 May Overcome Key PARP Resistance Mechanisms
LP-184 May Overcome Key PARP Resistance Mechanisms Resistance Mechanism Cause & Clinical Evidence LP-184 Overcoming Impact 1 Increased drug efflux Upregulation of ABC transporters Clinical evidence: No evidence LP-184 is not a substrate of major ABC transporters 2 Decreased PARP Loss / decreased tra
Slide 17: Financial Updates Q2 2026
Financial Updates Q2 2026 Summary Results of Operations Balance Sheet Highlights & Summary Three Months Ended June 30, (unaudited) 06/30/2026 12/31/2025 2026 2025 (unaudited) Operating expenses: Cash, Cash Equivalents & 7,361,255 10,119,224 Marketable Securities General and administrative $ 1,717,23
Slide 18: Connect With Us
NASDAQ: LTRN CONNECT WITH US FROM IDEA TO MEDICINE AT THE SPEED OF INSIGHT IR Contact: IR@lanternpharma.com 1-972-277-1136 www.lanternpharma.com open-medicine.ai @LanternPharma withzeta.ai linkedin.com/company/lanternpharma